Q-omics provides the consensus-scored TMOD1 profile across patient tissues and cancer cell-line models. TMOD1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in BLCA. Among the 18 cancer types available for tumor–normal comparison, TMOD1 is differentially expressed in 15, with the highest sampling consensus in BLCA. Additionally, TMOD1 protein abundance shows 31,289 significant protein co-abundance associations, with the highest sampling consensus in LUAD. Together, these results highlight BLCA, and LUAD as cancer lineages where TMOD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TMOD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TMOD1 survival associations across molecular data types. TMOD1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TMOD1 RNA expression–survival associations across cancer types. High TMOD1 expression shows unfavorable associations in BLCA, KIRP and STAD, but favorable associations in ACC, MESO and KIRC. The BLCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BLCA as the clearest survival context for TMOD1 RNA expression.
This table summarizes TMOD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15, while mass-spec protein shows differences in 9. The strongest signals are observed in THCA for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for TMOD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TMOD1 shows lower tumor expression in BLCA, THCA, COAD, KIRC, LUAD and LUSC. The BLCA box plot shows higher TMOD1 RNA expression in normal versus tumor tissue (log2 FC = −4.587, t-test p < 0.001).
This table shows molecular features associated with TMOD1 in patient tissues and cancer cell lines. In patient samples, TMOD1 shows the broadest associations at the RNA and protein expression levels, with LUAD recurring as the lineage with the largest associated feature set. In cancer cell lines, TMOD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and BLOOD_Leukemia.
